Aerpio Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ARPO Aerpio Pharmaceuticals Inc
FDC First Data Corp
SYMC Symantec Corp
PID Invesco International Dividend Achievers ETF
KAMAX Kensington Managed Income Fund Class A Shares
ATO Atmos Energy Corp
CI Cigna Corp
CF CF Industries Holdings Inc
ATI Allegheny Technologies Inc
AROC Archrock Inc

Health Care : Pharmaceuticals | Company profile

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:
  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    3:58p ET 06/19/19
  • Last (size)
  • 52-Wk Range
    0.88 - 4.95
  • (06/25/18 - 03/29/19)
  • 146.2%
  • Market Cap
  • Shares Outstanding
  • -0.36
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • --
  • 23.25
  • (% of float 05/31/19)

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.